This webinar will include a review of the pathophysiology of iMCD and how it applies to the development of current and emerging treatments. The expert faculty will discuss clinical trial data for current and emerging therapies, with a focus on efficacy, safety, appropriate dosing and formulations, drug-drug interactions, and pandemic-related considerations. Case studies will illustrate how pharmacists can apply evidence-based guideline recommendations to develop patient treatment plans.
- Introduction to Castleman Disease
- Pathophysiology of iMCD
- Optimizing Treatment of iMCD With Guideline-Recommended Therapies
- Faculty Panel Discussion
This activity has been designed to address the educational needs of pharmacists in general, but specifically clinical pharmacists and hematology and oncology pharmacists. It will also benefit other clinicians interested in the management patients with CD.
Click on the link for more information and to register: http://www.paradigmmc.com/1056
Release Date: October 29, 2021
Expiration Date: October 29, 2022
Time to Complete Activity: 1.0 hour